tm logo
Dead/Abandoned
ABANDONED - NO STATEMENT OF USE FILED

no statement of use filed

on 17 Apr 2023

Last Applicant/ Owned by

245 First Street

Cambridge

MA

02142

Serial Number

88202403 filed on 21st Nov 2018

Registration Number

N/A

Correspondent Address

Anessa Kramer

Anessa Kramer

39400 WOODWARD AVENUE, SUITE 101

BLOOMFIELD HILLS MI 48304-5151

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

Logo Mark Trademark Information

Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematolo Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds

Mark Details


Serial Number

No 88202403

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 267166449412

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.01.09 -

Geometric figures, objects, humans, plants or animals forming or bordering the perimeter of a circle

26.05.15 -

Four or more triangles

26.05.21 -

Triangles that are completely or partially shaded

Legal History


Show more

Status DateAction Taken
17th Apr 2023ABANDONMENT - NO USE STATEMENT FILED
17th Apr 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
04th Oct 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03rd Oct 2022SOU EXTENSION 5 GRANTED
31st Aug 2022SOU TEAS EXTENSION RECEIVED
31st Aug 2022SOU EXTENSION 5 FILED
03rd Mar 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28th Feb 2022SOU TEAS EXTENSION RECEIVED
28th Feb 2022SOU EXTENSION 4 FILED
28th Feb 2022SOU EXTENSION 4 GRANTED